AR064545A1 - Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona - Google Patents

Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona

Info

Publication number
AR064545A1
AR064545A1 ARP070105913A ARP070105913A AR064545A1 AR 064545 A1 AR064545 A1 AR 064545A1 AR P070105913 A ARP070105913 A AR P070105913A AR P070105913 A ARP070105913 A AR P070105913A AR 064545 A1 AR064545 A1 AR 064545A1
Authority
AR
Argentina
Prior art keywords
trifluor
fluor
piperazin
phenyl
methyl
Prior art date
Application number
ARP070105913A
Other languages
English (en)
Spanish (es)
Inventor
Urs Schwitter
Emmanuel Pinard
Andre Gerard Bubendorf
Annette Deynet-Vucenovic
Ralph Diodone
Olaf Grassmann
Kai Lindenstruth
Franziska Rohrer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38988312&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR064545(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR064545A1 publication Critical patent/AR064545A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
ARP070105913A 2006-12-28 2007-12-27 Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona AR064545A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06127269 2006-12-28

Publications (1)

Publication Number Publication Date
AR064545A1 true AR064545A1 (es) 2009-04-08

Family

ID=38988312

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105913A AR064545A1 (es) 2006-12-28 2007-12-27 Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona

Country Status (33)

Country Link
US (5) US20080214561A1 (https=)
EP (1) EP2114405B1 (https=)
JP (1) JP4799666B2 (https=)
KR (1) KR101130146B1 (https=)
CN (1) CN101573114A (https=)
AR (1) AR064545A1 (https=)
AU (1) AU2007341356B2 (https=)
BR (1) BRPI0720829B8 (https=)
CA (1) CA2673667A1 (https=)
CL (1) CL2007003830A1 (https=)
CO (1) CO6190613A2 (https=)
CR (1) CR10846A (https=)
CY (1) CY1116350T1 (https=)
DK (1) DK2114405T3 (https=)
EC (1) ECSP099471A (https=)
ES (1) ES2535040T3 (https=)
HR (1) HRP20150573T1 (https=)
HU (1) HUE025032T2 (https=)
MA (1) MA31029B1 (https=)
MX (1) MX2009006859A (https=)
MY (1) MY188367A (https=)
NO (1) NO342150B1 (https=)
NZ (1) NZ577502A (https=)
PE (1) PE20081556A1 (https=)
PL (1) PL2114405T3 (https=)
PT (1) PT2114405E (https=)
RS (1) RS53910B1 (https=)
RU (1) RU2463295C2 (https=)
SI (1) SI2114405T1 (https=)
TW (1) TWI388552B (https=)
UA (1) UA100232C2 (https=)
WO (1) WO2008080821A1 (https=)
ZA (1) ZA200904423B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009006859A (es) 2006-12-28 2009-07-03 Hoffmann La Roche Formas cristalinas de glyt1.
JP6074142B2 (ja) * 2009-02-26 2017-02-01 タール ファーマシューティカルズ，インコーポレイテッド 医薬化合物の結晶化
KR101196354B1 (ko) * 2010-09-03 2012-11-01 서유헌 퇴행성 신경계 뇌 질환의 예방 또는 치료용 약학 조성물
CN104334550A (zh) * 2012-05-25 2015-02-04 巴斯夫欧洲公司 1,5-二甲基-6-硫代-3-(2,2,7-三氟-3-氧代-4-(丙-2-炔基)-3,4-二氢-2H-苯并[b][1,4]噁嗪-6-基)-1,3,5-三嗪烷-2,4-二酮的晶型B
US8927412B1 (en) * 2013-08-01 2015-01-06 Taiwan Semiconductor Manufacturing Company, Ltd. Multi-chip package and method of formation
MX354615B (es) * 2013-10-02 2018-03-08 Centro De Investig Y De Estudios Avanzados Del I P N Uso del propilparabeno comoagente neuroprotector en el daño neuronal inducido por status epilepticus.
KR20220125326A (ko) 2020-01-09 2022-09-14 디스크 메디슨, 인크. 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법
JP7096956B2 (ja) * 2020-07-13 2022-07-06 日本碍子株式会社 精製方法
EP4337199A4 (en) * 2021-05-14 2025-03-19 Disc Medicine, Inc. Methods for treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibition agents
CN118043050A (zh) * 2021-05-27 2024-05-14 迪斯克医药公司 用固体形式的比托哌汀治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL154370A0 (en) 2003-02-10 2003-09-17 Chemagis Ltd Solid amorphous mixtures, processes for the preparation thereof and pharmaceutical compositions containing the same
RS53252B (sr) * 2003-08-11 2014-08-29 F.Hoffmann-La Roche Ag. Piperazin sa or-supstituisanom fenil grupom i njihova upotreba kao inhibitora glyt1
MX2009006859A (es) 2006-12-28 2009-07-03 Hoffmann La Roche Formas cristalinas de glyt1.

Also Published As

Publication number Publication date
AU2007341356B2 (en) 2013-08-29
EP2114405A1 (en) 2009-11-11
US20120309969A1 (en) 2012-12-06
NO342150B1 (no) 2018-04-03
CY1116350T1 (el) 2017-03-15
AU2007341356A1 (en) 2008-07-10
HUE025032T2 (en) 2016-02-29
JP2010514725A (ja) 2010-05-06
NZ577502A (en) 2012-02-24
BRPI0720829B8 (pt) 2021-05-25
TW200833677A (en) 2008-08-16
UA100232C2 (uk) 2012-12-10
US20080214561A1 (en) 2008-09-04
MA31029B1 (fr) 2009-12-01
KR20090094166A (ko) 2009-09-03
CN101573114A (zh) 2009-11-04
US20130197225A1 (en) 2013-08-01
SI2114405T1 (sl) 2015-06-30
PE20081556A1 (es) 2008-11-28
ZA200904423B (en) 2010-05-26
US20110295007A1 (en) 2011-12-01
BRPI0720829B1 (pt) 2020-04-07
DK2114405T3 (en) 2015-04-07
ES2535040T3 (es) 2015-05-04
PL2114405T3 (pl) 2015-08-31
US20100311971A1 (en) 2010-12-09
MY188367A (en) 2021-12-06
MX2009006859A (es) 2009-07-03
CO6190613A2 (es) 2010-08-19
CR10846A (es) 2009-08-12
CA2673667A1 (en) 2008-07-10
RU2009124113A (ru) 2011-02-10
KR101130146B1 (ko) 2012-03-28
HRP20150573T1 (xx) 2015-07-03
RU2463295C2 (ru) 2012-10-10
WO2008080821A1 (en) 2008-07-10
ECSP099471A (es) 2009-07-31
NO20092358L (no) 2009-06-22
PT2114405E (pt) 2015-06-02
EP2114405B1 (en) 2015-03-11
US8039473B2 (en) 2011-10-18
TWI388552B (zh) 2013-03-11
RS53910B1 (sr) 2015-08-31
JP4799666B2 (ja) 2011-10-26
BRPI0720829A2 (pt) 2014-02-25
CL2007003830A1 (es) 2008-07-11

Similar Documents

Publication Publication Date Title
AR064545A1 (es) Formas cristalinas de glyt1 [4-(3-fluor-5-trifluormetil-piridin-2-il)-piperazin-1-il]-[5-metanosulfonil-2-((s)-2,2,2-trifluor-1-metil-etoxi)-fenil]-metanona
NO20060768L (no) 1-(2-amino-benzol)-piperazinderivater som glycinopptaks-inhibitorer for behandling av psykoser
TW200734311A (en) New compounds
TNSN06042A1 (en) Piperazine with or-substituted phenyl group and their use as glyt 1 inhibitors
WO2007058583A3 (en) Novel 2-amino-heterocycles useful in the treatment of abeta-related pathologies
TN2011000493A1 (en) 1-heterocyclyl -1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin -4- one derivatives and their use as pde9a modulators
WO2015095337A3 (en) PYRAZOLO[1,5-a]PYRIMIDINECARBOXAMIDE DERIVATIVES FOR TREATING COGNITIVE IMPAIRMENT
CU20090184A7 (es) Compuestos amino-heterocíclicos
TW201144302A (en) 2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
WO2007143523A3 (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
WO2007002220A3 (en) Aminoacetamide acyl guanidines as beta-secretase inhibitors
EA201291413A1 (ru) Производные 3-амино-5,6-дигидро-1h-пиразин-2-она, применимые для лечения болезни альцгеймера и других форм деменции
BRPI0515528A (pt) n-metil hidroxietilamina úteis no tratamento de condições do sistema nervoso central
MX2019007100A (es) Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
ATE502026T1 (de) Verbindungen mit kombinierten cannabinoid-cb1- antagonismus und acetylcholinesterasehemmung
ATE501153T1 (de) Kristallisation von festen formen von clopidogreladditionssalzen
NZ593279A (en) Aroylamino - and heteroaroylamino-substituted piperidines as glyt-1 inhibitors
EA200702039A1 (ru) 7-аминоалкилиденилгетероциклические хинолоны и нафтиридоны
EA200702004A1 (ru) Соль безилата 7-(2-(4-(3-трифторметилфенил)-1,2,3,6-тетрагидропирид-1-ил)этил)изохинолина, ее получение и применение в терапии
DE602004026597D1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
IS8184A (is) Aðferð við framleiðslu á handhverfulega hreinu mírtasapíni
ATE496534T1 (de) Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit
RU2007125380A (ru) Сульфанил-замещенные фенилметаноны в качестве ингибиторов переносчика глицина 1 (glyt-1) для лечения неврологических и психоневрологических заболеваний

Legal Events

Date Code Title Description
FC Refusal